Tumor Heterozygosity Loss May Explain Failure of Studies to Link CYP2D6, Tamoxifen Benefit | GenomeWeb

NEW YORK (GenomeWeb) — Mayo Clinic researchers have demonstrated in a new study that measuring CYP2D6 status from breast tumor tissue can be inaccurate due to loss of heterozygosity in the CYP2D6 gene region. The authors argue that this may be the reason why some large studies have failed to show a connection between CYP2D6 genotype and response to tamoxifen.

The group published the study online this month in the Journal of the National Cancer Institute.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.